Topline PhIII data bode well as Lilly's dulaglutide girds for diabetes battle
This article was originally published in Scrip
Eli Lilly reported topline data from three Phase III clinical trials that showed the higher of two once-weekly doses for the long-acting glucagon-like peptide 1 (GLP-1) analogue dulaglutide (LY2189265) met the trials' primary endpoints, while both the 0.75mg and 1.5mg doses were statistically superior to three other drugs in the treatment of type 2 diabetes.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.